Tag Archives: NASDAQ:AKRX

Healthcare Sector Recap: Vivus Inc. (NASDAQ:VVUS) Falls as Loss Swells in 3Q – VVUS, AKRX, JNJ

Posted on November 7, 2012 by Geoff Noir

Healthcare sector was able to eke out gains on Tuesday session with a positive change of 0.06% with having 14% of the companies below the 2% level and 53% falling in below +2%.

Vivus Inc. (VVUS), manufacturer of the freshly …

Posted in Healthcare, Latest Headlines | Tagged Akorn, AKRX, JNJ, Johnson, NASDAQ:AKRX, NASDAQ:VVUS, NYSE:JNJ, Vivus, VVUS | Comments Off

Three Healthcare Stocks’ Drug Approval Battle with FDA – VPHM, AKRX, WPI

Posted on April 10, 2012 by Geoff Noir

Viropharma Inc (NASDAQ:VPHM) announced that the US Food and Drug Administration deprived of a petition associated to formative bioequivalence for its top selling drug, Vancocin, and the biopharmaceutical firms plans to look for an injunction to block the FDA’s authorization …

Posted in Healthcare, Latest Headlines | Tagged Akorn, AKRX, NASDAQ:AKRX, NASDAQ:VPHM, NYSE:WPI, Viropharma, VPHM, Watson Pharmaceuticals, WPI | Comments Off

Tuesday’s mixed bag of stocks (CLDX, AKRX, AMAT)

Posted on January 17, 2012 by Cameron White

In this report: Celldex Therapeutics (NASDAQ:CLDX), Akorn (NASDAQ:AKRX) and Applied Materials (NASDAQ:AMAT).

Celldex Therapeutics (NASDAQ:CLDX) gained more than 17 percent on Tuesday after the company announced the initiation of it Phase 1 clinical trial of its hematopoietic growth factor, CDX-301. …

Posted in Latest Headlines, Main Post | Tagged Akorn, AKRX, AMAT, analyst, Applied Materials, Buy, Celldex Therapeutics, CLDX, company, develop, earn, expectations, firm, fiscal, growth, NASDAQ, NASDAQ:AKRX, NASDAQ:AMAT, NASDAQ:CLDX, price target, profit, rating, RBC Capital, revenue, Roth Capital, share, tech, upgrade | Comments Off

What’s up Akorn, Pharmasset and Corinthian Colleges?

Posted on November 1, 2011 by Cameron White

In this report: Akorn Inc. (NASDAQ:AKRX), Pharmasset Inc. (NASDAQ:VRUS) and Corinthian Colleges (NASDAQ:COCO).

Akorn Inc. (NASDAQ:AKRX) has gained more than 11 percent today after the company reported a record third quarter. The company reported revenue of $36.7 million, up 69 …

Posted in Latest Headlines, Reports | Tagged 2012, adjusted, Akorn Inc., AKRX, Analysts, clinical trials, COCO, company, Corinthian Colleges, drug, earnings, EBITDA, experimental, fiscal, full-year, hepatitis C, late stage, marketing approval, NASDAQ:AKRX, NASDAQ:COCO, NASDAQ:VRUS, net income, outlook, Pharmasset Inc., predicted, profits, quarter, reported, results, revenue, ribavirin, trades, VRUS, Wall Street | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

Tag Archives: NASDAQ:AKRX

Healthcare Sector Recap: Vivus Inc. (NASDAQ:VVUS) Falls as Loss Swells in 3Q – VVUS, AKRX, JNJ

Three Healthcare Stocks’ Drug Approval Battle with FDA – VPHM, AKRX, WPI

What’s up Akorn, Pharmasset and Corinthian Colleges?

Follow us

Most Popular Posts

blogs